Compare Abeona Therapeutics Inc (ABEO) vs Amcor PLC (AMCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Amcor PLC — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Amcor PLC trades at $41.86 (market cap $20.55B). The key difference: Amcor PLC is far larger — about 55× Abeona Therapeutics Inc's market cap, and Amcor PLC pays a 5.85% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AMCR | |
|---|---|---|
Market Cap | $373.32M | $20.55B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $50.58 |
52-Week Low | $4.17 | $36.69 |
Enterprise Value | $228.22M | $35.67B |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMCR trades at $44.45, down 1.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $15.01B in 2025, with net income of $511M, and has beaten EPS estimates for the last three quarters. Recent news highlights sustainable packaging partnerships and leadership changes aimed at growth.
The stock offers a moderate upside to the consensus price target of $45.75, supported by a 69% analyst buy rating, but faces risks from integration challenges post-Berry acquisition and a high P/E ratio of 35.84. Earnings growth and synergy realization are key catalysts for 2027 recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
